Testagen

Testagen (KEDG; Lys–Glu–Asp–Gly) is described as an anterior pituitary–derived bioregulator peptide studied in preclinical models for endocrine modulation, with emphasis on the pituitary–gonadal axis and broader hormone normalization signals. The protocol’s mechanism description suggests these short peptides may act through gene-regulatory mechanisms that influence hormone synthesis and secretion, rather than binding a single classical receptor. The page cites avian hypophysectomy models in which KEDG was reported to normalize thyroid hormone parameters and influence thyroid morphology, supporting the idea that pituitary-derived peptide signals can modulate downstream endocrine organs. It also references work suggesting modulation of male reproductive hormone signaling via pituitary pathways. The protocol emphasizes that no published human clinical trials exist and that all dosing approaches are extrapolated from preclinical and in vitro data. In short, Testagen is positioned as an investigational endocrine bioregulator with limited direct human evidence but a mechanistic hypothesis centered on gene expression and pituitary-axis regulation.